Ordering
Available Variants5 mg
CHA.70508-5mg
Price
€58.14
Available – Dispatch in 14 days
25 mg
CHA.70508-25mg
Price
€177.48
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
5 mg | CHA.70508-5mg | €58.14 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
25 mg | CHA.70508-25mg | €177.48 |
≥98% (HPLC), ErbB tyrosine kinase inhibitor, solid
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C24H25ClFN5O3· 2HCl |
|---|---|
| CAS Number | 289499-45-2 |
| Molecular Weight | 558.86 |
| UNSPSC Code | 51111800 |
| PubChem Substance ID | 329775143 |
| NACRES | NA.77 |
| MDL number | MFCD09954112 |
| Assay | ≥98% (HPLC) |
| Form | solid |
| Quality level | 100 |
Safety Information Handling visibility
| pictograms |
GHS07
 GHS07
|
|---|---|
| signalword | Warning |
| hcodes | H315,H319,H335 |
| pcodes | P261 - P264 - P271 - P280 - P302 + P352 - P305 + P351 + P338 |
| Hazard Classifications | Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3 |
| target_organs | Respiratory system |
| Storage Class | 11 - Combustible Solids |
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
CI-1033, also known as canertinib, is a tyrosine kinase inhibitor with a CAS number of 289499-45-2. It is a small molecule that has been investigated for its potential therapeutic applications in the treatment of various cancers. CI-1033 has been shown to inhibit the activity of several members of the erbB family of receptor tyrosine kinases, including epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and HER4. This inhibition can lead to the suppression of tumor cell growth and proliferation, making CI-1033 a potential candidate for the treatment of cancers that are driven by the activity of these kinases. Further research is needed to fully explore the therapeutic potential of CI-1033 and to determine its safety and efficacy in clinical settings. Its mechanism of action and potential benefits are being studied in various preclinical and clinical trials.
